Overall mean age was 58.6 years, duration of diabetes was 13.7 years, HbA1c was 8.8%, body weight was 90.8 kg, BMI was 33.2 kg/m 2 , median insulin glargine dose was 46.0 IU/day (0.53 IU/kg/day) and 85.6% of participants were using metformin
Sarah Martinez, MD, FACP, board-certified in internal medicine and obesity medicine
Adoption by outpatient clinics has lagged, hindered by limited staffing for injectable patient training
For individuals with type 2 diabetes, the SUSTAIN-7 trial ( The Lancet Diabetes & Endocrinology , 2018) demonstrated that semaglutide lowered HbA1c levels by approximately 1.4%, outperforming other GLP-1 receptor agonists like dulaglutide